The Panelâ€™s report, â€śPromoting Value, Affordability, and Innovation in Cancer Drug Treatment,â€ť finds that while some cancer drugs have indeed been transformative, and may warrant prices that reflect their value, many new drugs do not provide benefits commensurate with their prices.

The Panelâ€™s report concludes that rapidly rising spending on cancer drugs is unprecedented and cannot be ignored, and that public-private collaboration is critical to ensure that patients receive high-quality cancer treatment and experience the best possible health outcomes without financial toxicity.

The Panel calls for action around three guiding principles:

Cancer drug prices should be aligned with their value to patients;

All patients should have affordable access to appropriate cancer drugs; and